Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.

@article{Yin2005PotentAO,
  title={Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.},
  author={Xiaoying Yin and Hong Zhang and Francis Burrows and Lin Zhang and Carol G. Shores},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2005},
  volume={11 10},
  pages={3889-96}
}
Heat shock protein 90 (Hsp90) is a molecular chaperone that promotes the conformational maturation of numerous client proteins, many of which play critical roles in tumor cell growth and survival. The ansamycin-based Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) is currently in phase I/II clinical testing. However, 17-AAG is difficult to formulate and displays weak activity against some tumors. A novel dimeric ansamycin, EC5, was evaluated for antitumor activity in eight head… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Hsp90 inhibitors as novel cancer Hsp90 Inhibitor Induces HNSCCCell Death Research. on May 1, 2017

L. Neckers
Clin Cancer Res • 2005

Cancer Statistics , 2004

A Jemal, R Tiwari
CACancerJClin • 2004

Targeting wide - range oncogenic transformation via PU 24 FCl , a specific inhibitor of tumor Hsp 90

M Vilenchik, D Solit
Chem Biol • 2004

Similar Papers

Loading similar papers…